LEIDEN, Netherlands & AARHUS, Denmark--(BUSINESS WIRE)--Today CLC bio announced the completion and final implementation of a specialized antibody engineering and selection module for Crucell, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that integrates with CLC bio’s bioinformatics platform. The specialized module is designed to optimize the end-to-end workflow and analysis pipeline when working with a large number of antibodies during the process of developing new therapies for various diseases amongst which infectious diseases and cancer
